Despite these advances, the median overall survival of patients who are diagnosed with locally advanced/metastatic NSCLC with no detectable EGFR mutation and/or ALK translocation and with PD-L1 staining > 1% remains lower than 3 years [9]. Here, ALK is linked to non-small cell lung carcinoma.